{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:01:38Z","timestamp":1784134898309,"version":"3.55.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,6,4]]},"DOI":"10.1001\/jama.2019.6717","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T16:52:29Z","timestamp":1559667149000},"page":"2101","source":"Crossref","is-referenced-by-count":60,"title":["Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"321","author":[{"given":"Sanjiv J.","family":"Shah","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"University of Glasgow, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Viethen","sequence":"additional","affiliation":[{"name":"Bayer AG, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonieta","family":"Bomfim Wirtz","sequence":"additional","affiliation":[{"name":"Bayer AG, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erya","family":"Huang","sequence":"additional","affiliation":[{"name":"Bayer United States, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos Ferenc","family":"Pap","sequence":"additional","affiliation":[{"name":"Bayer AG, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"joi190050r1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction.","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"issue":"19","key":"joi190050r2","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction.","volume":"375","author":"Redfield","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"joi190050r3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.jacc.2012.08.004","article-title":"Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction.","volume":"60","author":"Lam","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"joi190050r4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"joi190050r5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap.","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"joi190050r6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamacardio.2019.0052","article-title":"Myocardial strain in the assessment of patients with heart failure: a review.","volume":"4","author":"Marwick","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"9","key":"joi190050r7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction.","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"joi190050r8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"joi190050r9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jchf.2017.10.014","article-title":"Relative impairments in hemodynamic exercise reserve parameters in heart failure with preserved ejection fraction: a study-level pooled analysis.","volume":"6","author":"Pandey","year":"2018","journal-title":"JACC Heart Fail"},{"key":"joi190050r10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-3-319-59659-4","article-title":"Partial adenosine A1 agonist in heart failure.","volume":"243","author":"Dinh","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"joi190050r11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","article-title":"Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.","volume":"21","author":"Greene","year":"2016","journal-title":"Heart Fail Rev"},{"issue":"15","key":"joi190050r12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"joi190050r13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11302-011-9274-3","article-title":"Partial adenosine A1 receptor agonists for cardiovascular therapies.","volume":"8","author":"Albrecht-K\u00fcpper","year":"2012","journal-title":"Purinergic Signal"},{"issue":"1","key":"joi190050r14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bph.13339","article-title":"Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to a1 -adrenoceptor stimulation in vivo.","volume":"173","author":"Puhl","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"4","key":"joi190050r15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jcph.v57.4","article-title":"Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure.","volume":"57","author":"Voors","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"joi190050r16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/ejhf.2018.20.issue-11","article-title":"Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.","volume":"20","author":"Voors","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"joi190050r17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials.","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"joi190050r18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ejhf.2017.19.issue-6","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"joi190050r19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","article-title":"Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"3","key":"joi190050r20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.apmr.2016.08.481","article-title":"Association between 6-minute walk test distance and objective variables of functional capacity after exercise training in elderly heart failure patients with preserved ejection fraction: a randomized exercise trial.","volume":"98","author":"Maldonado-Mart\u00edn","year":"2017","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"joi190050r21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"joi190050r22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/10543406.2013.813519","article-title":"An adaptive two-stage dose-response design method for establishing proof of concept.","volume":"23","author":"Franchetti","year":"2013","journal-title":"J Biopharm Stat"},{"issue":"10","key":"joi190050r23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models.","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Stat Med"},{"issue":"27","key":"joi190050r24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"joi190050r25","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines.","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"joi190050r26","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America.","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"joi190050r27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"15","key":"joi190050r28","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jama\/article-pdf\/321\/21\/2101\/17623666\/jama_shah_2019_oi_190050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T16:52:30Z","timestamp":1559667150000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2019.6717"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":28,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,6,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.6717","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,4]]}}}